Adverse Effects of ATG/ALG Therapy in Aplastic Anemia
A Study on the Dynamics and Grading Criteria Construction of Adverse Reactions to ATG/ALG Therapy in Aplastic Anemia
Institute of Hematology & Blood Diseases Hospital, China
200 participants
Feb 23, 2026
OBSERVATIONAL
Conditions
Summary
This prospective, single-center, observational cohort study aims to systematically observe and describe the clinical characteristics of adverse reactions in patients with aplastic anemia undergoing ATG (Anti-Thymocyte Globulin) /ALG (Anti-Lymphocyte Globulin) treatment, providing a data foundation for the development of relevant management strategies. This study plans to enroll 200 aplastic anemia patients undergoing ATG/ALG treatment
Eligibility
Inclusion Criteria2
- Meet the diagnostic criteria for aplastic anemia (Camitta criteria);
- Receiving ATG/ALG immunosuppressive therapy for the first time;
Exclusion Criteria2
- Previously received hematopoietic stem cell transplantation;
- Aplastic anemia patients receiving ATG/ALG as part of transplant conditioning regimen;
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will receive ATG/ALG according to standard dosing protocols as per clinical guidelines. During treatment, we will monitor and document any adverse reactions, including their type, severity, duration, and any necessary interventions or changes in treatment plan.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07461116